Subacromial Injections for Shoulder Subacromial Pain Syndrome - Anterolateral vs Posterior Approach

Subacromial Injections for Shoulder Subacromial Pain Syndrome - Comparing Anterolateral Versus Posterior Approach: A Randomised Controlled Trial

This study aims to determine if there is any difference in terms of pain relief in patients with shoulder subacromial pain syndrome, when given a steroid injection into the subacromial space via an anterolateral approach compared to a posterior approach.

Study Overview

• Status: Not yet recruiting
• Conditions: Shoulder Subacromial Pain Syndrome
• Intervention / Treatment: Procedure: Anterolateral subacromial steroid injection; Procedure: Posterior subacromial steroid injection

Detailed Description

Patients who present with subacromial pain syndrome (disorders such as subacromial bursitis, rotator cuff tendinopathy, calcific tendinitis, subacromial inflammation with a partial thickness rotator cuff tear) to the orthopaedic outpatient clinic are treated initially with a subacromial steroid injection in addition to physiotherapy for a period of 3 months. This applies to patients who have had no other treatments previously as well as to patients who have had previous physiotherapy or steroid injections prior to presentation. Patients who do not want to undergo the treatment offered are either treated with simple analgesia, sole physiotherapy or surgery.

When a patient with one of the above conditions agrees to go ahead with a steroid injection followed by physiotherapy, the steroid injection is given at the earliest opportunity. The steroid injection is given into the subacromial space either using the anterolateral (front-side) approach (1 cm below and behind the anterior edge of the acromion with the needle aiming towards the under surface of the acromion) or using the posterior (back-side) approach ( 1cm inferior and medial to the posterlateral acromial edge with the needle pointing towards the anterolateral aspect of the acromion). The exact approach is determined according to the preference of the person carrying out the injection. As a routine we use a 10ml syringe containing 10mls of 0.25% Marcaine along with 40mg triamcinolone with an 18 gauge (green) needle. It is normal for patients to complain of some discomfort during the injection. If a patient experiences any significant discomfort or they cannot tolerate the injection for whatever reason, then the injection is discontinued and is not reattempted using a different approach.

Following the injection, patients are questioned on any discomfort experienced during the injection and on whether or not their pain has improved. They are then taken through a protocol of physiotherapy for their shoulder over the subsequent 3 months. A protocol is issued for guidance however therapists are allowed to use other modalities as per their discretion. The frequency of appointments with physiotherapy will depend on patient's symptoms as well as their progression. For study purposes a frequency record of these meetings will be kept and matched to the overall OSS. Patients are seen routinely in 3 months following an injection in order to assess any improvement in symptomatology using the OSS, visual analogue score, DASH and SF36 questionaires. If the symptoms have improved then no further intervention is taken. Further OSS, visual analogue pain score, DASH and SF36 questionaires will be posted out at 6 months and 1 year. On the other hand, if they are still troubled with symptoms then the possibility of further injections or surgery is discussed.

The aim of this study is to compare the two approaches that are currently used for subacromial steroid injections, namely the anterolateral and posterior approach, with regards to their effectiveness in improving shoulder symptoms. There will be no deviation from our routine protocol other than randomising patients who agree to participate in this study to either the anterolateral or posterior approach.

In summary, it is patients who are seen in clinic with a subacromial pathology and subsequently diagnosed with shoulder subacromial pain syndrome, who are offered an injection. Those who agree to have an injection will then be invited to participate in the study. An information leaflet will be given to all potential participants and they will be allowed sufficient time to read through it, digest all the information and ask any questions they may have before making a decision regarding their participation. Those who agree to participate will be randomly allocated, using sealed envelopes to one of the two approaches for the injection. The injection will then be administered via the selected approach by a clinician who is qualified in carrying out the procedure. Patients will be asked about any discomfort experienced during the injection, improvement in pain following the injection prior to leaving hospital and overall satisfaction with the injection. Following this patients will have physiotherapy as an outpatient as routine and will be seen at about 3 months post injection for a further assessment at the clinic. Again the shoulder assessment will be repeated on that occasion. Shoulder assessment questionaires will be posted out for completion at 6 months and 1 year (OSS, pain on visial analogue scale, DASH and SF36) There will be no change in patients care from routine practice other than the randomisation of the approach used for the injection. Patients who are invited to participate in the study and agree to participate will have their GP informed of their participation.

Assessments

1. Prior to injection: assessment of pain using a visual analogue score, clinical assessment of shoulder movement and completion of a modified Oxford Shoulder Score, Disabilities of Shoulder, Arm and Hand questionaires and Short Form 36 Health Survey.
2. 20-30 minutes Post injection: assessment of pain using a visual analogue score
3. Prior to leaving hospital: pain experienced during the administration of the injection and the overall satisfaction with the injection
4. 3 months post injection: assessment of pain using a visual analogue score, clinical assessment of shoulder movement and completion of a modified Oxford Shoulder Score, Disabilities of Shoulder, Arm and Hand questionaires and Short Form 36 Health Survey.
5. 6 months and 1 year post injection: assessment of pain using visual analogue score and completion of a modified Oxford Shoulder Score, Disabilities of Shoulder, Arm and Hand questionaires and Short Form 36 Health Survey via post.

The main outcome for this study will be the Oxford Shoulder Score (OSS) at 3 months post-injection. In addition to the standard OSS, the questionnaire will inquire about general symptoms and signs, duration, hand dominance, previous injuries to the shoulder and previous treatments to the shoulder. The follow up questionnaire will be identical to the initial questionnaire but excluding questions on previous treatments, hand dominance, injuries and duration.

Other demographics that will be recorded on the pre-designed pro forma include: number and frequency of physiotherapy sessions pre and post injection, and subsequent need for further management.

Hard copies of data (questionnaires and forms) collected will be placed into the patient's notes. At the same time this data will be recorded electronically on an Excel database and saved on an encrypted, password protected memory stick. This memory stick will be stored in a locked filing cabinet in the orthopaedic department at Blackpool Victoria Hospital. Please note: The electronic data will contain NO identifiable information. Participants will be identified by a unique study I.D number which can only be linked to them by members of the research team.

• Study Type: Interventional
• Enrollment (Anticipated): 86
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Maureen Morgan; Phone Number: +441253955453; Email: maureen.morgan1@nhs.net

Study Locations

• United Kingdom
  • Blackpool, United Kingdom, FY3 8NR
    • Blackpool Teaching Hospitals NHS Foundation Trust
    • Contact: Maureen Morgan; Phone Number: +441253955453; Email: maureen.morgan1@nhs.net
    • Principal Investigator: Charalambos Charalambous
    • Sub-Investigator: John T Hirst

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient diagnosed with shoulder subacromial pain syndrome
• Age ≥ 18
• Capacity to give valid consent for participation
• Able to complete the follow up

Exclusion Criteria:

• Age < 18
• Lacking capacity/unable to give valid consent for participation
• Full thickness rotator cuff tear diagnosed on either Ultrasound scan or Magnestic Resonance Imaging
• Unable to complete follow up
• Unable to speak or read English

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Anterolateral Approach; The randomised group of patients receiving the subacromial steroid injection via an anterolateral approach	Procedure: Anterolateral subacromial steroid injection; Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach
Active Comparator: Posterior Approach; The randomised group of patients receiving the subacromial steroid injection via a posterior approach	Procedure: Posterior subacromial steroid injection; Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Oxford Shoulder Score	The primary outcome measure will be the change in the Oxford Shoulder Score at 3 months post injection. Scores range from 0-48 with 48 being the best possible outcome.	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Oxford Shoulder Score	Change in the Oxford Shoulder Score at 6 months and 1 year post injection. Scores range from 0-48 with 48 being the best possible outcome.	6 months and 1 year
Pain on visual analogue scale	Change in pain on the visual analogue scale at 3 months, 6 months and 1 year post injection. As this is a visual analogue scale this is a visual scale with no numeric values attached however on the left side of the scale will be no pain and the right side will be maximal pain.	3 months, 6 months and 1 year post injection
Disabilities of Arm, Shoulder and Hand Questionnaire	Change in the Disabilities of Arm, Shoulder and Hand Questionnaire score at 3 months, 6 months and 1 year post injection. This is a score that ranges from 0-100 with 0 meaning no disability and 100 meaning most severe disability.	3 months, 6 months and 1 year
Short Form 36 Health Survey Score	Change in the Short From 36 Health Survey Score at 3 months, 6 months and 1 year post injection. This is a range from 0-100 with the higher the score, the less disability.	3 months, 6 months and 1 year

Collaborators and Investigators

• Sponsor: Blackpool Teaching Hospitals NHS Foundation Trust
• Investigators: Principal Investigator: Charalambos Charalambous, Consultant Orthopaedic Surgeon

Study record dates

Study Major Dates

• Study Start (Anticipated): November 1, 2019
• Primary Completion (Anticipated): November 1, 2022
• Study Completion (Anticipated): April 1, 2023

Study Registration Dates

• First Submitted: October 30, 2019
• First Submitted That Met QC Criteria: November 19, 2019
• First Posted (Actual): November 20, 2019

Study Record Updates

• Last Update Posted (Actual): November 25, 2019
• Last Update Submitted That Met QC Criteria: November 21, 2019
• Last Verified: November 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Disease; Syndrome; Somatoform Disorders
• Other Study ID Numbers: 249246

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No